Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. Transactions on Cancer
  4. Vol 4, Issue 1, 2023

Expression and Clinical Significance of SATB1 Gene in Urothelial Carcinoma of Bladder

Download as PDF

DOI: 10.23977/tranc.2023.040112 | Downloads: 5 | Views: 350

Author(s)

Pei Zhang 1, Mingkai Liu 2, Shun Zhang 1, Yuanfang Sun 3

Affiliation(s)

1 Department of Pathology, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China
2 Department of Urology, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China
3 Department of Radiology, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China

Corresponding Author

Yuanfang Sun

ABSTRACT

Urothelial carcinoma of bladder is a highly malignant urological tumor, and its occurrence and development are regulated by multiple genes. This article selected 40 cases of bladder urethral epithelial cell carcinoma confirmed by pathology in the urology department of the hospital from 2020 to 2021. Mutations in the SATB1 (Special AT-rich Binding protein 1) gene can cause changes in thousands of genes, which have a significant impact on the development and metastasis of cancer. Moreover, the incremental regulation of SATB1 is likely to be a key gene cluster switch leading to cancer metastasis. This article used SP immunohistochemistry to detect the expression of SATB1 gene in bladder urothelial carcinoma cells and verify its function, in order to lay a foundation for future research and clinical application. The positive rate of SATB1 protein was 56.3%, and the negative rate of SATB1 protein was 43.7%.

KEYWORDS

SATB1 Gene, Urothelial Carcinoma of Bladder, Gene Regulation, Distant Metastasis, Clinical Significance

CITE THIS PAPER

Pei Zhang, Mingkai Liu, Shun Zhang, Yuanfang Sun, Expression and Clinical Significance of SATB1 Gene in Urothelial Carcinoma of Bladder. Transactions on Cancer (2023) Vol. 4: 80-88. DOI: http://dx.doi.org/10.23977/tranc.2023.040112.

REFERENCES

[1] Yang Tao, Wang Gang, Sun Fuzhen, et al. The effect of miR-34a on Beclin1 mediated autophagy and gemcitabine chemotherapy sensitivity in bladder urothelial cell carcinoma cells. Chinese Journal of Gerontology, 2023, 43 (2): 384-388.
[2] Ji Bozhong, Xia Chengmao, Luo Yongyou, Chen Dongge, Liu Bin, Yang Yanli, Ma Yingchun. Clinical and pathological analysis of 7 cases of bladder urothelial cell carcinoma with occasional prostate cancer. Chinese Journal of Clinical and Experimental Pathology, 2022, 38 (9): 1062-1065.
[3] Wang Zihua, Wu Hongzhen, Liang Yingying, Yang Ruimeng, Mo Lei, Zhang Jiaxiang. Prediction of histological grading of bladder urothelial cell carcinoma based on enhanced CT imaging omics model. Chinese Journal of Medical Imaging, 2022, 30 (11): 1166-1170.
[4] Mou Dongyun, Zhang Yanjin, Jiang Liren, et al. The expression of p-STAT3 and PD-L1 in bladder urothelial cell carcinoma and their relationship with clinical pathological features. Chongqing Medicine, 2023, 52 (9): 1330-1333.
[5] Lin Zhiyuan, Lu Lili, Chen Pu, et al. Predictive effect of peripheral blood immune cells on the efficacy of PD-1 monoclonal antibody in the treatment of advanced bladder urothelial cell carcinoma. Chinese journal of Clinical Medicine, 2023, 30 (1): 49-55. 
[6] A, Baojie Ma, et al. Radical cystectomy for pT1 urothelial carcinoma of bladder not amenable to TURBT: Long-term results. European Journal of Surgical Oncology, 2019, 45(10):1993-1999.
[7] Abrahamsson, J, Sjodahl, et al. Decreasing number of circulating tumor cells in patients with urothelial carcinoma of the bladder undergoing preoperative chemotherapy and association with downstaging of the primary tumor after cystectomy: an interim analysis. Clinical and Experimental Metastasis, 2018, 35(3):206-207.
[8] Abufaraj, M., Foerster, B., Schernhammer, E., Moschini, M., Kimura, S., & Hassler, M., et al. Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes - ScienceDirect. European Urology, 2019, 75(4):649-658.
[9] Bolenz, Christian, Knauf, et al. Decreased Invasion of Urothelial Carcinoma of the Bladder by Inhibition of Matrix-Metalloproteinase 7.Bladder cancer. 2018, 4(1):67-75.
[10] Fan J, Liang H, Fan J, et al. Diagnostic accuracy of cystoscopic biopsy for tumour grade in outpatients with urothelial carcinoma of the bladder and the risk factors of upgrading. Asian Journal of Urology (English), 2023, 10(1):19-26.
[11] Fraune C, Simon R, Hube-Magg C, et al. MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass - ScienceDirect.Urologic Oncology: Seminars and Original Investigations, 2020, 38( 5):488-495.
[12] Maria, Del, Carmen, et al. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder. Virchows Archiv, 2019, 475(3):349–356.
[13] Mastroianni R, Brassetti A, Salhi Y A, et al.MP72-03 Assessing the Impact of Absence of Detrusor Muscle in Ta-lg Urothelial Carcinoma of the Bladder on Recurrence Free Survival. The Journal of Urology, 2020, 203(Supplement 4):e1073-e1074.
[14] Miyake M, Hori S, Morizawa Y, et al. Altered deposition of collagens promote tumor budding at the tumor invasion front in urothelial carcinoma of the bladder. European Urology Supplements, 2018, 17(2):e1519-e1520.
[15] Moriyama H, Nakano Y, Kadonishi Y, et al. Lymphoma-like/plasmacytoid variant of invasive urothelial carcinoma of the bladder: A report of two cases. Nishinihon Journal of Urology, 2019, 81(2):215-222.
[16] Novikov M E, Meleshko N A, Akopyan I G .Tulium laser in urothelial carcinoma of the bladder with spread to the ostium of the ureter. Cancer Urology, 2020, 16(3):198-204.
[17] Patrick H, Matthew P, Natasha K, et al. MP65-16 Novel Biomarker Signature for Predicting Pathologic Response of Urothelial Carcinoma of the Bladder to Cisplatin-Based Neoadjuvant Chemotherapy. Journal of Urology, 2018, 199(4):e864-e865.
[18] Suren D, Yildirim H T, Atalay I,et al. HMGB1 expression in urothelial carcinoma of the bladder. Journal of B.u.on. Official Journal of the Balkan Union of Oncology, 2018, 23(6):1882-1886.
[19] Tripathi K, Goel A, Singhai A, et al. Mutational analysis of Ras hotspots in patients with urothelial carcinoma of the bladder. World journal of clinical oncology, 2020, 11(8):614-628.
[20] Wahyuni S D, Suryanti S, Agustina H, et al. The Association of Clinicopathological Features with Metastatic Status in Infiltrative Urothelial Carcinoma of Bladder. Journal of Drug Delivery and Therapeutics, 2020, 10(6-s):99-102.
[21] Wei W, Yang M Z, Liu T Q, et al. Characteristics and clinical significance of mixed grade nonmuscle invasive urothelial carcinoma of urinary bladder. Chinese Journal of Cancer Prevention and Treatment, 2018, 25(11):812-820.
[22] Y F Yu, X L Zhou, G F Wang, et al. Clinicopathological analysis of micropapillary urothelial carcinoma of the bladder. Zhonghua bing li xue za zhi Chinese journal of pathology, 2021, 50(2):125-127.
[23] Zattoni F, Giannarini G, Crestani A, et al. MP65-08 the Neutrophil-To-Lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy. Journal of Urology, 2018, 199(4):e861-e862.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 420
Visits: 28108

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.